HaraldReinhartMD

Infectious Disease • Randolph, NJ

Physician

Join to view full profile

Dr. Reinhart is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Reinhart's full profile

Already have an account?

Office
17 Timber Ln
Randolph, NJ 07869
Phone+1 973-989-5695

Education & Training

Detroit Medical Center/Wayne State UniversityFellowship, Infectious Disease, 1986 - 1987
Drexel University College of Medicine/Hahnemann University HospitalResidency, Internal Medicine, 1981 - 1984
University of Wurzburg Faculty of MedicineClass of 1978

Certifications & Licensure

MI State Medical License 1986 - 2026
American Board of Internal Medicine Internal Medicine

Publications & Presentations

PubMed

48 citations
Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus comp...
Keith S Kaye, Andrew F Shorr, Richard G Wunderink, Bin Du, Gabrielle E Poirier
The Lancet. Infectious Diseases. 2023-09-01
24 citations
In vitro activity of sulbactam/durlobactam against clinical isolates of Acinetobacter baumannii collected in China
Qiwen Yang, Yingchun Xu, Peiyao Jia, Ying Zhu, Jingjia Zhang
The Journal of Antimicrobial Chemotherapy. 2020-07-01
19 citations
Antimicrobial Activity of Omadacycline Tested against Clinical Bacterial Isolates from Hospitals in Mainland China, Hong Kong, and Taiwan: Results from the SENTRY Anti...
Cecilia G Carvalhaes, Michael D. Huband, Harald H Reinhart, Robert K. Flamm, Helio S. Sader
Antimicrobial Agents and Chemotherapy. 2019-02-26

Press Mentions

Zai Lab Announces First Patient Dosed in Greater China in Global Registrational Clinical Trial of Efgartigimod in CIDPNovember 16th, 2021
Zai Lab and Crescendo Biologics Enter Exclusive Worldwide License Agreement for Innovative Protein Therapeutics for Inflammatory IndicationsMay 30th, 2018
Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 as a Topical Treatment for Chronic Plaque PsoriasisMay 25th, 2024